Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Exclusive Article
The Cannabis Sector's Billion-Dollar Tax CutSubmitted by Jeffrey Neal Johnson. First Published: 4/23/2026. 
Key Points
- A major administrative policy shift is normalizing the tax structure for the cannabis industry, directly enhancing the financial standing of licensed operators.
- The largest multi-state operators are now positioned to leverage their significant revenues to generate substantial free cash flow for growth and expansion.
- This financial normalization shifts the investment focus from speculative policy hopes toward the tangible business fundamentals of established market leaders.
- Special Report: The Biggest IPO Ever: Claim Your Stake Today
On the heels of the executive order to fast-track research into psychedelic drugs, a second major federal policy shift on April 23, 2026, is sending waves through the cannabis sector. Many on Wall Street have misunderstood the real catalyst: the administration's decision to move state-licensed medical marijuana from Schedule I to Schedule III of the Controlled Substances Act is not the same as federal legalization. Instead, the real story is a surgical financial change in the U.S. tax code that could unlock billions in value for a select group of companies. For investors, this move rewrites the industry's rulebook — shifting the sector from an era of speculative hope toward one driven by tangible cash flow. It creates a clearer playbook for identifying potential profitability in the cannabis market. How the Death of 280E Changes Everything
For a moment…
Forget about Trump’s ties to Israel.
Forget about reports of Iran’s nuclear program.
Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason. Click here to find out what it is.
For more than a decade, U.S. cannabis companies have been uniquely penalized by Internal Revenue Code Section 280E. Originally designed in the 1980s to prevent illegal drug traffickers from claiming tax deductions, the rule was applied to state-legal cannabis businesses. In practical terms, licensed companies could not deduct ordinary and necessary business expenses from taxable income. Imagine a typical retail business being unable to deduct store rent, payroll, or marketing. Cannabis operators were effectively taxed on gross profit rather than net income, producing crushing effective tax rates that often exceeded 70%. Moving state-licensed medical marijuana to Schedule III effectively eliminates the application of 280E for those licensed medical operators. That change allows them to operate like other businesses, reducing their effective tax rate to the standard corporate rate of roughly 21%. The valuation implications are straightforward and powerful. This administrative change functions like a massive, non-dilutive infusion of cash onto company balance sheets. It should immediately improve reported net income and earnings per share (EPS), providing management teams with hundreds of millions of dollars in newfound capital that can be used to fund growth, pay down debt, or return value to shareholders instead of being sent to the IRS. The New Kings of Cannabis Cash FlowWhile the sector-wide reaction has been enthusiastic, the fiscal benefits will not be distributed evenly. The biggest advantage — a meaningful, non-dilutive boost to liquidity — will accrue primarily to leading U.S. Multi-State Operators (MSOs) with dominant revenue streams and established operating infrastructures. The Profitability KingGreen Thumb Industries (OTCMKTS: GTBIF) stands out as a potential gold standard. It has been one of the few major MSOs to consistently generate positive net income despite the 280E tax burden, reporting trailing net income of $114.15 million. With a price-to-earnings ratio (P/E) of about 15 before the policy change, Green Thumb's profitability is positioned to expand materially. That additional cash flow could be directed into marketing its consumer brands — including Rythm and Dogwalkers — potentially accelerating market-share gains in key states. The Scale and Shareholder Return PlayWith more than $1.27 billion in annual sales, Curaleaf (OTCMKTS: CURLF) benefits from scale that could produce some of the largest absolute tax savings in the industry. The company underscored this new financial reality by announcing an $83 million share buyback program. A buyback is a classic signal from a company with excess cash. The timing — announced days before the official policy shift — can be read as management expressing confidence even ahead of the administrative change. That shift from survival-mode to shareholder returns could attract value-oriented investors. The High-Leverage and Strategic Plays: Trulieve, Verano, and Cresco LabsSeveral MSOs appear positioned to deploy tax savings into aggressive growth. Trulieve Cannabis (OTCMKTS: TCNNF), with dominant market share in Florida and strong political connections, may use its savings to fortify its position ahead of a potential adult-use legalization ballot measure. Meanwhile, companies such as Cresco Labs (OTCMKTS: CRLBF), which recently secured a medical license in Texas, and Verano Holdings (OTCMKTS: VRNOF), which simplified its corporate structure by redomiciling to Nevada, now have the internal capital to fund expansion without taking on as much debt or diluting shareholders. The Tilray Contrast: Know What You OwnWhen cannabis headlines break, many investors gravitate to familiar, NASDAQ-listed names like Tilray Brands, Inc. (NASDAQ: TLRY), assuming over-the-counter (OTC) names are too risky. Tilray is among the most liquid and widely held stocks in the sector and is often used to trade sector sentiment. But Tilray's business model differs materially from U.S. MSOs. Its operations are primarily focused on the Canadian adult-use market, international medical markets in Europe, and a growing U.S. presence centered on craft beverage brands like SweetWater Brewing. Because Tilray is not a U.S. plant-touching operator and was not subject to the punitive U.S. 280E tax, it does not receive the direct financial uplift from this specific catalyst. For investors focused on the impact of the Schedule III move, Tilray may be more of a sympathy trade than a primary beneficiary. The Green Wave: A New Era for Cannabis ProfitsMoving medical cannabis to Schedule III is a partial but highly consequential win. It does not legalize cannabis at the federal level, enable interstate commerce, or automatically clear the path for uplisting to major U.S. exchanges such as NASDAQ. Those remain meaningful barriers that investors should continue to monitor. However, by normalizing the industry's tax treatment, the change gives the strongest U.S. operators a clearer path to build durable financial positions. The urgency around federal banking reform remains, but it is less acute now that top MSOs can generate substantial internal cash flow to fund operations and expansion. The investment playbook has shifted. The focus should move away from speculating on sweeping federal reform and toward analyzing the fundamentals of U.S. MSOs that can convert these tax savings into sustainable earnings. While the industry has not received a full legal all-clear, it has received an official financial one. Investors interested in the sector may want to add leading U.S. MSOs to their watchlists and watch upcoming quarterly earnings for management's first formal guidance in a post-280E environment. |
Tiada ulasan:
Catat Ulasan